Summary – A new market study, “2025 World Anticancer Drugs Market Research Report by Product Type, End-User / Application and Regions / Countries”has been featured on WiseGuyReports.Antineoplastic drugs, also known as anticancer drugs, anti-malignant drugs, refer to drugs for the treatment of malignant tumors.Simply put, there are chemotherapy drugs and biological agents.In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of tumors; the invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry, and genetic engineering have accelerated the process of drug development; research and development of anti-tumor drugs have been Enter a new era.Also Read: https://www.medgadget.com/2019/10/anticancer-drugs-2019-global-market-net-worth-us-163400-million-forecast-by-2025.html At present, there are more than 80 kinds of anti-cancer drugs commonly used in clinical practice in the world, which can be roughly divided into the following 6 categories: cytotoxic drugs, hormone drugs, biological response modifiers, monoclonal antibody drugs, other drugs, and auxiliary drugs.The global Anticancer Drugs market is valued at 89300 million US$ in 2018 and will reach 163400 million US$ by the end of 2025, growing at a CAGR of 7.9% during 2019-2025.The objectives of this study are to define, segment, and project the size of the Anticancer Drugs market based on company, product type, end user and key regions.Also Read: https://icrowdnewswire.com/2020/09/14/semiconductor-inspection-system-market-innovations-trends-technology-and-applications-market-report-to-2020-2025/ This report studies the global market size of Anticancer Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Anticancer Drugs in these regions.This research report categorizes the global Anticancer Drugs market by top players/brands, region, type and end user.This report also studies the global Anticancer Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.Also Read: http://www.marketwatch.com/story/hookah-charcoal-market-2020-global-trends-market-share-industry-size-growth-opportunities-and-market-forecast-to-2026-2021-01-11 The following manufacturers are covered in this report, with sales, revenue, market share for each company:Hoffmann-La Roche LtdEli Lilly and CompanyCELGENE CORPORATIONNovartis AGPfizer IncAmgen IncBayer AGAstraZenecaTakeda Pharmaceutical Company LimitedMerck & Co. Market size by ProductCytotoxic Drugs (Alkylating Agents, and Antimetabolites)Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)Hormonal DrugsMarket size by End UserLung CancerBreast CancerLeukemiaColorectal CancerAlso Read: http://www.marketwatch.com/story/global-kanban-software-market-2020-segmentation-demand-growth-trend-opportunity-and-forecast-to-2025-2021-01-08 Market size by RegionNorth AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaSingaporeMalaysiaPhilippinesThailandVietnamEuropeGermanyFranceUKItalySpainRussiaCentral & South AmericaBrazilRest of Central & South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth AfricaAlso Read: http://www.marketwatch.com/story/breakfast-biscuit-global-market-2021-share-growth-trend-industry-analysis-and-forecast-to-2026-2021-01-06 The study objectives of this report are:To study and analyze the global Anticancer Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.To understand the structure of Anticancer Drugs market by identifying its various subsegments.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).Focuses on the key global Anticancer Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.To project the value and sales volume of Anticancer Drugs submarkets, with respect to key regions.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.In this study, the years considered to estimate the market size of Anticancer Drugs are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025 This report includes the estimation of market size for value (million US$) and volume (K Units).
The global craniomaxillofacial devices market to grow at a CAGR of 7% during 2020-2025.Craniomaxillofacial (CMF) devices stand for the equipment deployed in several orthopedic surgeries.These devices are generally utilized for treating severe cranial and facial bone injuries using medical implants.The few variants of CMF implants are bone-graft substitutes, cranial flap fixtures, screws and bolts that are majorly used in CMF distraction, thoracic fixation and temporomandibular joint replacement.Other than orthopedic surgeries, these devices are also adopted in plastic surgery, neurosurgery, orthognathic and dental surgeries.The growing incidences of cranial fractures coupled with the rising inclination towards minimally-invasive (MI) facial reconstruction surgeries are augmenting the demand for CMF devices.In addition to this, the increasing adoption of CMF devices in the treatment of numerous neuro-oncology ailments, neurovascular disorders, spinal- or skull-based injuries, etc., is further catalyzing the craniomaxillofacial devices market growth.
January 20, 2021:  The global Biopsy Devices Market size is estimated to reach USD 2.3 billion by 2020, exhibiting a 6.4% CAGR during the forecast period.Growing incidence of cancer and rising demand pertaining to patient’s unmet need for accurate diagnosis is expected to drive the market forward in the coming years.Rising income levels and growing modern healthcare infrastructure has increased the life expectancy considerably.Aforementioned factors are anticipated to propel progress in this market.Rising cancer incidence is anticipated to drive the demand for this technology thus leading to substantial growth over the forecast period.As per American Cancer Society, by the end of 2030, the global cancer burden is estimated to reach 21.7 million with respect to number of cases and reach 13 million cancer deaths.Advantages associated with the use of these procedures include less invasiveness and fast recovery as compared to the conventional approaches.As a consequence of increase in demand for procuring internal organ samples from soft tissue sources such as prostate gland, kidneys, bone marrow, and breast tissues this segment is anticipated to witness fastest growth.Technological innovations drive the progress rate of the market.For instance, Aspirational syringe gun developed by INRAD Inc. is gaining huge popularity due to the novel technology incorporated in the same.
The Global Optical Coherence Tomography Market (OCT) Size is anticipated to reach over USD 2,179.75 Million by 2026 according to a new research published by Polaris Market Research.Optical Coherence Tomography (OCT) methods are operative optical diagnostics techniques that cast a 2D as well as the 3D outlook of the retina to help ophthalmological assessments and treatments.The OCT market has been emphasized by the advancement in technologies, furthered by the increasing significance of medical applications in the current scenario.The range of Optical Coherence Tomography is not limited to ophthalmology and has extended across other medical application such as nephrology, dermatology, and oncology.This factor has amplified the growth scenarios of the Optical Coherence Tomography (OCT) which is anticipated to show intense growth in the forecast period.Furthermore, the non-intrusive nature of OCT has made this technique a prime choice of the medical community for ophthalmic imaging.Request for sample copy of this report @  https://www.polarismarketresearch.com/industry-analysis/global-optical-coherence-tomography-oct-market/request-for-sample The Optical Coherence Tomography (OCT) market has extended its area to the study of ailments such as cardiovascular disruptions, diabetes, esophageal problems, non-melanoma skin cancer, and prostate cancer.In addition, the emerging economies such as China, Japan, and India have seen operational variations in their healthcare sector which is making developing progress in that regions.
Market ScenarioThe global wearable injectors market is expected to grow significantly over the forecast period.It is estimated that the global wearable injectors market is expected to register a CAGR of ~ 15.2% during the forecast period from 2018 to 2023.For instance, in July 2016, Amgen received US Food and Drug Administration (FDA) approval for its on-body wearable injector, Repatha (evolocumab) Pushtronex system, a human monoclonal antibody injector.Moreover, favorable healthcare investments by government and the rising demand for minimally invasive devices boosts the growth of the market.However, stringent government regulation for product approval and the growing preference for traditional methods of drug delivery may hamper the market growth during the assessment period.SegmentationThe global wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.The market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.The market, by usage, has been segmented into disposable and semi-reusable.The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.Key playersWest Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG are some of the key players in the global wearable injectors market.Regional Market SummaryGeographically, the Americas is anticipated to dominate the global wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure.
2
Market SynopsisThe global breast imaging market is considered to demonstrate 8.5% CAGR during the forecast period (2017-2023) owing to increasing prevalence of breast cancer, asserts Market Research Future (MRFR).Among these, mammography is the most widely used screening tool and diagnosis for breast cancer and helps to detect breast cancer at an early stage.The increasing expenditure on healthcare by the developed countries coupled with the technological developments in the field of oncology across the world has further contributed to the market growth.For instance, companies like GE Healthcare have recently launched a commercial regarding the awareness of breast density and its effect on screening techniques.With the increasing awareness, the demand for breast imaging is predicted to expand in during the appraisal period.On the flip side, the high cost of breast imaging solutions coupled with the unawareness about breast imaging among the women population are predicted to dampen the market growth during the estimated period.This is considered to restrict the market growth in the coming years.Global Breast Imaging Market: Segmental AnalysisThe global breast imaging market has been segmented on the basis of type, application, deployment, end-user, and region.By mode of type, the global breast imaging market has been segmented into CT, mammography, MRI, PET, breast biopsy, ultrasound, tactile imaging, and others.
Factors driving the global market include introduction of new and advanced products, investment for the modernization of diagnostic imaging centers, development of new radiotracers, and increasing incidence and prevalence of cancer & cardiovascular diseases.However, factors such as shutdown of National Research Universal (NRU) reactor, high cost of nuclear imaging equipment, and shorter half-life of radiopharmaceuticals are hindering the growth of the market.The report Nuclear Imaging Equipment Market is expected to reach USD 2.85 Billion by 2021 from USD 2.25 Billion in 2016, growing at a CAGR of 4.8%.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=98Market Segmentation:-The global nuclear imaging equipment market is segmented on the basis of product, application, end user, and region.Based on product, the Positron Emission Tomography Market is categorized into SPECT systems, hybrid PET systems, and planar scintigraphy.In 2016, the SPECT systems segment is expected to account for the largest share of the nuclear imaging equipment market.The SPECT systems are further segmented into hybrid SPECT and standalone SPECT systems.In 2016, the hybrid SPECT segment is expected to account for the largest share of the SPECT PET Market.Based on application, the nuclear imaging equipment market is segmented into oncology, cardiology, neurology, and other applications (orthopedics, urology, thyroid-related disorders, and gastroenterology).In 2016, the oncology application segment is expected to account for the largest share of the nuclear imaging equipment applications market.Based on end user, the Positron Emission Tomography Market is segmented into hospitals, imaging centers, academic & research centers, and other end users (pharmaceutical & biotechnology companies and CROs).
The global Enteral Feeding Tube market report provides insight into the current situation of the market and predicts the recent future over the duration of 2020 to 2025.The information mentioned in the report helps to decide the marketing strategies, wheatear to enter in the market, and to know the financial condition of the key players operating in the market for quite some time.Additionally, it helps to decide the target audience and to strategies the marketing to seize the opportunities at right time.The data provided in report gives the most useful insights over the environment navigation, supply chain assessment, and consumption of products in terms of revenue and volume both.In addition, the market research report provides segmental analysis such as segmental revenue, performance segment in particular region, and future estimation for next five years.Furthermore, it assess with the local and international supply chain companies working in the market.For Right Perspective & Competitive Insights, Request a Sample @: https://introspectivemarketresearch.com/request/200Key Player Mentioned: Abbott, Fresenius Kabi, Danone, Nestle, Halyard Health, Cook Medical, B. Braun, Boston Scientific, Vygon, Conmed, C. R. Bard, Cardinal Health and Applied MedicalProduct Segment Analysis: Gastrostomy Tube, Nasoenteric Tube and OtherApplication Segment Analysis: Oncology, Gastroenterology, Neurology, Diabetes and OtherRegional Segment Analysis: USA, Europe, Japan, China, India, South East AsiaResearch Methodology: Research methodologies adopted by the research analysts to conduct a comprehensive research on the global Enteral Feeding Tube market are unique and trustworthy.Prime strategical activities in the market, such as Enteral Feeding Tube market share, product developments, mergers and acquisitions, partnerships, etc., are also discussed in detail.
The new report by Expert Market Research titled, ‘Global Contract Research Organization (CRO) Services Market Price Trends, Growth, Report and Forecast 2020-2025’, gives an in-depth analysis of the global contract research organization (CRO) services market, assessing the market based on its segments like service types, therapeutic areas, end uses, and major regions.The sample report shall be delivered to you within 24 hours.Get a Free Sample Report with Table of Contents – https://www.expertmarketresearch.com/reports/contract-research-organisation-cro-services-market/requestsampleThe key highlights of the report include:Market Overview (2015-2025)• Historical Market Size (2019): USD 42 Billion• Forecast CAGR (2020-2025): 7%• Forecast Market Size (2025): USD 63 BillionThe expiration of patents, the advent of generic drugs, and advances in technology, such as mHealth and big data, have an effect on drug development, leading to greater outsourcing of testing to CROs.CROs are gaining increasing prominence due to an increase in the number of drug development projects across the nations.Read Full Report with Table of Contents – https://www.expertmarketresearch.com/reports/contract-research-organisation-cro-services-marketIndustry Definition and Major SegmentsContract research organisation (CRO), variously known as clinical research organisation, is a term used to refer to a contract-based corporation that offers research-related support to the pharmaceutical, biotechnology, and medical device industries.Contract research organisation services are important to the pharmaceutical, biomedical, and MedTech industries.These services help client efforts to study, test, change, and market new pharmaceutical and medical devices.The market segmentation based on service type is as follows:• Early Phase Development• Discovery Services• Chemistry• Preclinical Services• Clinical Research Services• Phase I• Phase II• Phase III• Phase IV• Laboratory Services• Bioanalytical Services• Analytical Services• Others• Consulting Services• Data Management Services• OthersThe market segmentation based on therapeutic area is as follows:• Oncology• Clinical Pharmacology• Cardiovascular• Infectious Disease• Neurology• Gastroenterology and Hepatology• Respiratory• OthersThe market segmentation by end use is:• Pharmaceutical and Biopharmaceutical Companies• Medical Device Companies• Academic Institutes• OthersThe market segmentation by region is:• North America• Europe• Asia Pacific• Latin America• Middle East and AfricaMarket TrendsThe growth in developing regions is expected to be higher due to the increasing investments in research and development activities and advantageous regulatory policies.While large corporations serve as premium CRO suppliers for many pharmaceutical and biotech companies worldwide, the small and medium-sized CROs concentrate on a more tailored approach and aim to grow in niche sectors.
Transparency Market Research (TMR) has published a new report titled, ‘Multiplexed Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.According to the report, the global multiplexed diagnostics market was valued at around US$ 8.7 Bn in 2018 and is projected to grow at a CAGR of 17.9% from 2019 to 2027.OverviewDiagnostic assays are tests used to assess target analytes, quantitatively or qualitatively, in biochemical substances, cells of an organism, or an organic sample for disease diagnosisMultiplexed diagnostics screen multiple analytes in a single cycle of assay procedure.Though single plex assays are widely available in the market, they fail to yield results for multiple analytes in a single cycle of assay process, and thus when multiple analytes are needed to be screened, cost and turnaround time of single plex assay is higher as compared to multiplexed assay.Rising demand for advanced diagnostic technology for accurate diagnosis of life-threatening diseases is the major factor to drive the global market.North America dominated the global multiplexed diagnostics market in 2018 and anticipated to dominate during the forecast period.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1719Significant private and public funding for genomics and personalized medicine to Drive MarketGrowing demand for automated equipment and multifaceted analytical strategies is the major driver for the growth of global multiplexed diagnostics market.Rising demand for advanced diagnostic technology for accurate diagnosis of life-threatening diseases and Increasing prevalence of cancer and infectious diseases are some of the major factors responsible for the growth of global multiplexed diagnostics marketFor instance, as per WHO 2010 data, Breast cancer is one of the most common causes of mortality among females, accounting for 25% of total cancer cases and 15% of cancer mortality across the world (WHO, 2010).Moreover significant private and public funding for genomics and personalized medicine is also fuelling the growth of global multiplexed diagnostics market.Medium Density Multiplexed Assays Segment to Dominate MarketBased on technology, the global multiplexed diagnostics market has been segmented into Very High Density Multiplexed Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low Density Multiplexed Assays, and Next Generation SequencingMedium Density Multiplexed Assays segment is accounted for major market share in 2018 and is expected to dominate throughout the forecast period owing to increasing use in genetic research.Increasing emerging diseases that need new diagnosis tests and new drug development create demand for high density multiplexed assaysCardiac Diseases- More Lucrative Application SegmentBased on application, the global multiplexed diagnostics market has been divided into Infectious Disease Diagnostic, oncology, autoimmune diseases, cardiac diseases, allergies, and othersOncology segment dominated the global market in 2018 due to Product developments that enable smooth, fast procedure for both the physician and patient, and increase in incidence of diseases associated with breast cancer, colorectal cancer, and prostate cancerCardiac diseases segment is more promising segment during the forecast period owing to rising prevalence of cardiac diseases and development of important biomarkers for cardiac disease detectionRequest for Analysis of COVID19 Impact on Multiplexed Diagnostics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=1719Academic research institutes Segment- Lion Market ShareBased on end-user, the global multiplexed diagnostics market has been segmented into academic research institutes, hospitals, diagnostic laboratories, pharmaceutical companies, and clinical research organizationsAcademic research institutes is accounted for major market share in 2018.Increasing research projects in the field of genetic engineering is the key factor driving the segment.Purchase Multiplexed Diagnostics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1719=SNorth America to Dominate Global MarketIn terms of region, the global multiplexed diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.North America accounted for major share of the global multiplexed diagnostics market in 2018.Increasing use of multiplexed diagnostics in academic and research institutes, large number of people with oncology and infectious diseases, several market players in the U.S., technological advancements, extensive R practices, and increasing awareness about the diagnosis and treatment are likely to boost market growth in the U.S.For instance, the University of California San Francisco (UCSF) has seven PCR installations for its academic researchThe multiplexed diagnostics market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027.This can be ascribed to growing aging population, high incidence of various diseases, and increased research activities in the region.Competitive LandscapeThe global multiplexed diagnostics market is consolidated as few players hold major market share in global market.Key players include Agilent Technologies, bioMérieux SA, Bio-Rad Laboratories, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Luminex Corporation, Siemens Healthineers, Thermo Fisher Scientific, Inc., Abbott Laboratories, among othersMore Trending Reports by Transparency Market Research:https://www.prnewswire.com/news-releases/magnifying-prevalence-of-malnutrition-and-other-disorders-to-add-extra-stars-of-growth-global-medical-foods-market-to-reach-valuation-of-us-33-3-bn-by-2030--301123806.htmlhttps://www.prnewswire.com/news-releases/technological-strides-in-ultrasound-devices-market-expand-scope-of-diagnosing-complex-diseases-market-to-clock-cagr-of-5-6-from-2018-to-2026-tmr-301129995.htmlAbout UsTransparency Market Research is a global market intelligence company, providing global business information reports and services.
Overview:Market Research Future (MRFR), in its attempt to understand the market proceedings, has revealed several factors that can impact the growth.The better technological influx and their easy integration in the mainstream, improvement in the infrastructure, and a rise in investment to boost the research works would help the global market achieve growth.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/7397The global plasma fractionation market is showing ample scope for growth and it is projected to secure a 6.5% CAGR during the forecast period of 2018 to 2023.Segmentation:The global market for plasma fractionation has been segmented by market researchers on the basis of product, application, and end user.By product, the global market study on the plasma fractionation has been segmented into coagulation factor concentrates, protease inhibitors, albumin, immunoglobulin, and others.The immunoglobulin segment has been segmented further into subcutaneous immunoglobulin (SCIG), intravenous immunoglobulin (IVIG), and others.By application, the global discussion on the plasma fractionation market includes neurology, hematology, immunology, hemato-oncology, pulmonology, rheumatology, critical care, and others.Various clinical research laboratories are impacting the global market as they are trying to develop new methods of treatments.
New York, NY 19 Jan 2021: The global theranostics market Size is anticipated to reach over USD 20.52 Billion by 2026 according to a new study published by Polaris Market Research.Theranostics are defined as a combination of diagnostics and drug therapeutics to improve the drug safety, drug restructures development and effectiveness.The increasing occurrence of life-threatening and chronic diseases and the demand for innovative chemotherapeutic treatments associated with the need for improving disease detection are the key factors propelling the global theranostics market.Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market/request-for-sample The global theranostics market is segmented on the basis of disease type, technology, and geography.On the basis of disease type, the global theranostics market is segmented into Neurological Disorders, Cardiovascular Diseases, Oncology Disorders, and Immunological Disorders.On the basis of technology, the global theranostics market is segmented into Polymerase Chain Reaction (PCR), In-situ Hybridization, Immunohistochemistry, and sequencing.
All types of cancer can show bone-metastasis.Urinary incontinence, bowel incontinence, and hypercalcemia are some of the common symptoms of the disease.According to a study published in the Oncology Reviews Journal in 2017, the relative occurrence of bone metastasis was estimated to be around 65 to 75% for both breast and prostate cancers suffering patients, respectively.According to the American Society of Clinical Oncology in 2016, approximately 60% of the total cancer patients aged 65 years or more.However, factors such as lack of healthcare services in low-income countries, the high cost of treatment, and related side effects are estimated to restrain the market growth during the forecast period.According to a study published in the Journal of Spine Surgery in 2017, the mean total cost of therapeutic modalities such as vertebroplasty was estimated to be about USD 14,114 in 2014.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5776The global bone metastasis market is expected to grow at an approximate CAGR of 8.4% during the forecast periodIntended AudiencePharmaceutical CompaniesBiotechnological InstitutesGovernment and Private LaboratoriesResearch and Development (R) CompaniesMedical Research LaboratoriesMarket Research and Consulting Service ProvidersSegmentationThe global bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.On the basis of type, the market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.On the basis of diagnosis, the market is categorized into biopsy, blood test, imaging, and others.
The global chemotherapy market report by Market Research Future (MRFR) looks at the various types of cancers and the impact of chemotherapy on their treatment for the period of 2019 to 2024 (forecast period).Market OutlookThe global chemotherapy market size is estimated to balloon to USD 56,491.59 million by 2024.Huge prevalence of cancer, large allocation of funds for research on cancer, and introduction of new reimbursement and medical insurance schemes are major drivers of the market.According to a recent publication in the Journal of Clinical Oncology, the addition of pembrolizumab to the mix of platinum methotrexate and chemotherapy for the treatment of patients with advanced squamous non-small-cell lung cancer (NSLC) had led to increased survival rate by a certain degree.Segmentation AnalysisThe global chemotherapy market is segmented into drug class, route of administration, indication, and end user.On the basis of drug class, the market is segmented into topoisomerase inhibitors, alkylating agents, mitotic inhibitors, antitumor antibiotic, and antimetabolites.The alkylating agents segment is expected to lead the market and score a substantial CAGR of 11.83% to reach USD 20,360.32 million by the end of 2024.On the basis of route of administration, the market is segmented into intraperitoneal, intravenous, intraventricular/intrathecal, subcutaneous, oral, intra-muscular, intravesicular, and topical.The large number of cancer cases, availability of advanced treatment, and attractive medical reimbursement schemes can fuel the Americas chemotherapy market growth.The Europe chemotherapy market can exceed a valuation of USD 18,292.73 million by 2024.Rise in the number of cancer cases, the increase in healthcare expenditure, and government awareness campaigns can have an indelible impact on the regional market.
The Medical And Diagnostic Laboratory Services Global Market Report 2020-30 by The Business Research Company describes and explains the global medical and diagnostic laboratory services market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030.The report evaluates the market across each region and for the major economies within each region.The Medical And Diagnostic Laboratory Services Global Market Report 2021 covers medical and diagnostic laboratory services market drivers, medical and diagnostic laboratory services market trends, medical and diagnostic laboratory services market segments, medical and diagnostic laboratory services market growth rate, medical and diagnostic laboratory services market major players, and medical and diagnostic laboratory services market size.View Complete Report:https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report-2020-30-covid-19-impact-and-recoveryThe medical and diagnostic laboratory services market report provides an in-depth analysis of the impact of COVID-19 on the global medical and diagnostic laboratory services industry, along with revised market numbers due to the effects of the coronavirus and the expected medical and diagnostic laboratory services market growth numbers 2021-2030.Medical And Diagnostic Laboratory Services Global Market Report 2021 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.The chapter also covers markets which have been positively affected by the pandemic.Request For The Sample Now:https://www.thebusinessresearchcompany.com/sample.aspx?id=1965=smpThe global medical and diagnostic laboratory services market is expected to grow from $115.89 billion in 2020 to $125.53 billion in 2021 at a compound annual growth rate (CAGR) of 8.3%.The market is expected to reach $157.45 billion in 2025 at a CAGR of 6%.The report covers the medical and diagnostic laboratory services market’s segments- 1) By Type: Diagnostic Imaging Centers, Medical Laboratory Services.2) By Application: Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Others.3) By End User Gender: Male, Female.4) By Type of Expenditure: Public, Private.Subsegments Covered: Computer Tomography (CT-Scan) Centers, Medical Radiological Laboratories, Dental or Medical X-Ray Laboratories, Ultrasound Imaging Centers, Magnetic Resonance Imaging (MRI) Centers.About The Business Research Company: The Business Research Company is a market intelligence firm that excels in company, market, and consumer research.
The global human microbiome therapeutics market size is expected to reach USD 1,544.6 million by 2027 according to a new study by Polaris Market Research.The report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, and Prescription Drugs); By Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders, Infectious Disease, Metabolic Disorders, Oncology, and Others); By Indication (Acne Vulgaris, Atopic Dermatitis, Clostridium difficile Infection, Colorectal Cancer, Diabetes, Inflammatory Bowel Disease (IBD), Lactose Intolerance, Lung Cancer, Non-alcoholic steatohepatitis (NASH), Obesity, and Coeliac Disease); By Approach (Small Molecule Therapies, Single Strain Whole Bacteria, Microbial Consortia, Genetically Modified Single Strain Bacteria, Phage Cocktail, and Microbial Ecosystems), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.Microbiome refers to the residing micro-organisms genomes in the human body, particularly in the gut.The human body comprises more than 100 trillion microbes and around 2 million microbe genomes.The majority of these are strict anaerobes, with fungi and archaebacteria comprising less than 1 per cent of the total population.Request for sample copy of this report @https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sampleThe global market is driven by an increased focus on microbiome based early diagnosis of diseases, increase in the prevalence of diseases due to dysbiosis, rising collaborations, and strongly funded government backed microbiome research projects.In November 2019, the Million Microbiome of Humans Project (MMHP) was launched in collaboration with France, Denmark, China, Latvia, Sweden and other countries to co-operate in meta-genomic research.The aim is to create the largest human microbiome database from analyzing more than one million samples gathered from reproductive tract, gut, skin, and other organs in the next few years.Market participants such as Enterome Bioscience, Biotagenics, Seres Therapeutics, Oxidien Pharmaceuticals, LLC, BoobyBiome, 4D Pharma PLC, UBiome, Carbiotix, E.I.
Market SynopsisA sentinel lymph node biopsy is a medical procedure, which involves identification, removal, and examination of the lymph node to verify the presence of cancer cells.Lymph nodes are a part of the lymphatic system which is found throughout the body and is connected to the lymph vessels.Breast cancer, melanoma, colon cancer, esophageal cancer, head and neck cancer, non-small cell lung cancer, stomach cancer, thyroid cancer are various indications for biopsy.However, various factors restrained the market growth such as complications associated with the biopsy and unawareness among women.The global sentinel node biopsy market is expected to grow at a CAGR of 5.1% during the forecast period.Key Players in the Global Sentinel Node Biopsy Market Some of the key players in this market are Devicor Medical Products, Inc., part of Leica Biosystems.(Germany), C. R. Bard, Inc. (U.S.), INTRAMEDICAL IMAGING LLC (U.S.), Hilfe Engineering Corporation (India), Surgic Eye (Germany), KUB Technologies, Inc. (U.S.), Navidea Biopharmaceuticals, Inc.(U.S.) and others.Sentinel Node Biopsy Market SegmentsThe global sentinel node biopsy market is segmented on the basic product, indication, and end user.On the basis of product, the sentinel node biopsy market is segmented into breast localization wire, tissue marker, gamma probe, drainage catheter, and othersOn the basis of indication, the sentinel node biopsy market is segmented into breast cancer, melanoma, colon cancer, esophageal cancer, and others.On the basis of the end user, the sentinel node biopsy market is segmented into hospitals & clinics, diagnostic centers, and others.Intended AudienceMedical Device ManufacturersMedical Device SuppliersMedical Research LaboratoriesHealthcare IT CompaniesResearch and Development (R) CompaniesMarket Research and Consulting Service ProvidersPotential InvestorsRegional Analysis of the Global Sentinel node biopsy Market             America captures the first position for sentinel node biopsy market is driven by increasing number of women suffering from breast disorders and rising prevalence of breast cancer in the U.S. and Canada.As per the American Cancer Society, in 2015, there were 231,840 new cases of breast cancer, and till March 2017, there were 3.1 million women with a history of breast cancer in the U.S. As per the National Cancer Institute, 2016, in the U.S. around 1,685,210 new cases of cancer were diagnosed and in 2014, around 15,780 children and adolescents ages 0 to 19 were diagnosed with cancer and 1,960 died of the disease.In Europe, sentinel node biopsy market shows better growth opportunities governed by the ongoing research and development activities in the field of oncology.
The Global Optical Coherence Tomography Market (OCT) Size is anticipated to reach over USD 2,179.75 Million by 2026 according to a new research published by Polaris Market Research.Optical Coherence Tomography (OCT) methods are operative optical diagnostics techniques that cast a 2D as well as the 3D outlook of the retina to help ophthalmological assessments and treatments.The OCT market has been emphasized by the advancement in technologies, furthered by the increasing significance of medical applications in the current scenario.The range of Optical Coherence Tomography is not limited to ophthalmology and has extended across other medical application such as nephrology, dermatology, and oncology.This factor has amplified the growth scenarios of the Optical Coherence Tomography (OCT) which is anticipated to show intense growth in the forecast period.The escalation of pathology has also become a devoted contributor to market growth as OCT methods could be employed in the pensive study of micro-level diseases.Furthermore, the non-intrusive nature of OCT has made this technique a prime choice of the medical community for ophthalmic imaging.Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/global-optical-coherence-tomography-oct-market/request-for-sampleThe Optical Coherence Tomography (OCT) market has extended its area to the study of ailments such as cardiovascular disruptions, diabetes, esophageal problems, non-melanoma skin cancer, and prostate cancer.
Global active pharmaceutical ingredients (API) market is registering a substantial CAGR of 7.17 % in the forecast period of 2020-2026.Active pharmaceutical ingredient (API) is the component of any drug that generates its effect.Some drugs, such as combination therapy, have various effective components to cure distinct diseases or to behave in distinct respects.Key Market Competitors:Few of the major market competitors currently working in the global active pharmaceutical ingredients (API) market are Pfizer Inc., Novartis AG, Sanofi, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company., GlaxoSmithKline plc., Merck Sharp & Dohme Corp., AbbVie Inc., AstraZeneca, Aurobindo Pharma, BASF SE, Dr. Reddy’s Laboratories Ltd., LUPIN., Mylan N.V., Sun Pharmaceutical Industries Ltd, Piramal Pharma Solutions, Sandoz International GmbH, Saneca Pharmaceuticals a. s and others.Download exclusive PDF sample [email protected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-active-pharmaceutical-ingredient-api-marketGenerally, the pharmaceutical companies themselves have produced APIs in their respective nations.But in latest years, many corporations have chosen to ship manufacturing abroad to reduce expenses.This has led to important modifications in the way these drugs are controlled, with more strict guidance and checks in location.Segmentation: Global Active Pharmaceutical Ingredients (API) MarketBy Type (Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients)By Type of Manufacturer (Captive API Manufacturers, Merchant API Manufacturers)By Type of Synthesis (Synthetic Active Pharmaceutical Ingredients, Biotech Active Pharmaceutical Ingredients)By Type of Drug (Prescription Drugs, Over-The-Counter Drugs)By Therapeutic Application (Communicable Diseases, Oncology, Pain Management, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Other Therapeutic Applications)By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)Competitive Analysis:Global active pharmaceutical ingredients (API) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.The report includes market shares of active pharmaceutical ingredients (API) market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Market DriversIncreased occurrence of chronic diseases is driving the growth of the marketTechnology advances in API Manufacturing is propelling the growth of the marketIncreasing generic significance is boosting the growth of the marketIncreasing implementation of artificial intelligence-based drug discovery instruments is contributing to the growth of the marketMarket RestraintsDrug costs monitoring strategies throughout countries is hampering the growth of the marketStrong rivalry among manufacturers of the API is hindering the growth of the marketGrowing development of anti-counterfeit drugs is restricting the growth of the marketReasons to Purchase this ReportCurrent and future of global active pharmaceutical ingredients (API) market outlook in the developed and emerging marketsThe segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast periodRegions/Countries that are expected to witness the fastest growth rates during the forecast periodThe latest developments, market shares, and strategies that are employed by the major market playersInquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-active-pharmaceutical-ingredient-api-marketCustomization of the Report:All segmentation provided above in this report is represented at country levelAll products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.
1
The new research report titled "Closed System Drug Transfer Device Market, Global Industry Analysis, and Forecast" gives a detailed analysis and future forecasts of the market.The report highlights the significant players, including market size, share, and demand, development.This report further covers the latest trends, technological advancements, and growth opportunities.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.The major players in the closed system drug transfer device market include BD Medical, Equashield, ICU Medical, Teva Medical Ltd., CorvidaMedical, B. Braun.This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Closed System Drug Transfer Device Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/closed-system-drug-transfer-device-market/download-sampleMarket DynamicsThe global closed system drug-transfer device market is driven by an increased risk of chromosomal abnormalities associated with hazardous drug exposure in all healthcare workers, rising cancer cases, a growing number of oncology drug approvals, and restricting regulatory guidelines regarding the safe handling and use of hazardous drugs.Meanwhile, limited technological progress and underdeveloped healthcare industry in some regions are projected to hamper the closed system transfer device (CSTD) market.
More

Top